<i>Burkholderia pseudomallei</i> D-alanine-D-alanine ligase:detailed characterisation and assessment of a potential antibiotic drug target by Díaz‐Sáez, Laura et al.
                                                              
University of Dundee
Burkholderia pseudomallei D-alanine-D-alanine ligase
Diaz Saez, Laura; Torrie, Leah; McElroy, Stuart; Gray, David; Hunter, Bill
Published in:
FEBS Journal
DOI:
10.1111/febs.14976
Publication date:
2019
Document Version
Publisher's PDF, also known as Version of record
Link to publication in Discovery Research Portal
Citation for published version (APA):
Diaz Saez, L., Torrie, L., McElroy, S., Gray, D., & Hunter, B. (2019). Burkholderia pseudomallei D-alanine-D-
alanine ligase: detailed characterisation and assessment of a potential antibiotic drug target. FEBS Journal.
https://doi.org/10.1111/febs.14976
General rights
Copyright and moral rights for the publications made accessible in Discovery Research Portal are retained by the authors and/or other
copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with
these rights.
 • Users may download and print one copy of any publication from Discovery Research Portal for the purpose of private study or research.
 • You may not further distribute the material or use it for any profit-making activity or commercial gain.
 • You may freely distribute the URL identifying the publication in the public portal.
Take down policy
If you believe that this document breaches copyright please contact us providing details, and we will remove access to the work immediately
and investigate your claim.
Download date: 10. Sep. 2019
Burkholderia pseudomallei D-alanine-D-alanine ligase;
detailed characterisation and assessment of a potential
antibiotic drug target
Laura Dıaz-Saez1, Leah S. Torrie2, Stuart P. McElroy3†, David Gray2 and William N. Hunter1
1 Division of Biological Chemistry and Drug Discovery, School of Life Sciences, University of Dundee, UK
2 Drug Discovery Unit, Wellcome Centre for Anti-Infectives Research, School of Life Sciences, University of Dundee, UK
3 European Screening Centre Newhouse, Biocity Scotland, University of Dundee, Newhouse, UK
Keywords
antibacterial; enzyme assay; enzyme
inhibition; peptidoglycan; target validation
Correspondence
W. N. Hunter, Division of Biological
Chemistry and Drug Discovery, School of
Life Sciences, University of Dundee, Dow
Street, Dundee DD1 5EH, UK
Tel: +44 (0)1382385745
E-mail: w.n.hunter@dundee.ac.uk
†Present address BioAscent Discovery
Ltd, Bo’ness Road, Newhouse,
Lanarkshire, ML1 5UH, UK
(Received 18 February 2019, revised 27
May 2019, accepted 27 June 2019)
doi:10.1111/febs.14976
Burkholderia pseudomallei is a serious, difficult to treat Gram-negative
pathogen and an increase in the occurrence of drug-resistant strains has
been detected. We have directed efforts to identify and to evaluate poten-
tial drug targets relevant to treatment of infection by B. pseudomallei. We
have selected and characterised the essential enzyme D-alanine-D-alanine
ligase (BpDdl), required for the ATP-assisted biosynthesis of a peptidogly-
can precursor. A recombinant supply of protein supported high-resolution
crystallographic and biophysical studies with ligands (AMP and AMP+D-
Ala-D-Ala), and comparisons with orthologues enzymes suggest a ligand-
induced conformational change occurring that might be relevant to the
catalytic cycle. The detailed biochemical characterisation of the enzyme,
development and optimisation of ligand binding assays supported the
search for novel inhibitors by screening of selected compound libraries. In
a similar manner to that observed previously in other studies, we note a
paucity of hits that are worth follow-up and then in combination with a
computational analysis of the active site, we conclude that this ligase repre-
sents a difficult target for drug discovery. Nevertheless, our reagents, pro-
tocols and data can underpin future efforts exploiting more diverse
chemical libraries and structure-based approaches.
Introduction
Burkholderia pseudomallei, a serious pathogen of humans
and animals, causes melioidosis. This Gram-negative
bacterium is widely distributed in the environment and is
classified as a Category B biowarfare agent by the U.S.
Centers for Disease Control and Prevention (CDC,
www.cdc.gov). Treatment of melioidosis involves intra-
venous high-intensity application of cephalosporins for
up to 2 weeks then an eradication phase to prevent recur-
rence that can involve the use of antifolate combinations
for up to 20 weeks. This is an expensive treatment often
complicated by side effects and a further issue is that
strains resistant to the current drugs have been identified
[1,2]. New antibacterial strategies are being considered [3]
and to this end, we sought to investigate the potential of
key enzymes as new therapeutic targets and to generate
the data, reagents and protocols that support an assess-
ment of these targets for early stage drug discovery.
The peptidoglycan (PG) layer contributes an impor-
tant protective shield for Gram-negative organisms
and antibiotics, such as b-lactams and glycopeptides,
indeed the key drug for melioidosis, ceftazidime, target
one or more enzymes required for its biosynthesis
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[4–7]. Due to the success of targeting parts of the PG
biosynthetic pathway [7], we focused on the assessment
of D-alanine-D-alanine (D-Ala-D-Ala) ligase as a poten-
tial target for the development of new drugs for
B. pseudomallei infections.
D-Alanine (D-Ala) contributes a key structural role
in the PG layer as a dipeptide, and in lantibiotics
[8–10]. The biosynthesis of D-Ala-D-Ala involves an
ATP-dependent ligase (Ddl, EC 6.3.2.4) [10,11]. In
some bacteria, for example Escherichia coli, there exist
two proteins (EcDdlA and EcDdlB) [12] with a
sequence identity of about 30%. At the time of writ-
ing, there are 587 reviewed Ddl sequences in UniProt
(www.uniprot.org), and 18 bacteria presenting two
Ddl proteins with sequence identities from 26% to
58%. A search for DdlA and DdlB sequences, per-
formed using NCBI BLAST [13], identified only DdlB in
B. pseudomallei (BpDdl).
Structures of DdlB from several bacteria have been
determined in the apo-form and ligand-bound com-
plexes [14,15]. Ddl presents the ATP-grasp family fold
[16], and the catalysed reaction follows a sequential
ordered mechanism [17,18]. Known inhibitors of Ddl
include D-cycloserine (DCS) [17–19], phosphinates
[15,20,21], diazenocarboxamides [22], hydroxyethy-
lamine [23] and boron derivatives of D-Ala [24]. How-
ever, there has been little progress in developing highly
potent inhibitors of Ddl with efficient engagement of
the cellular target. This might be due to the polar nat-
ure of these inhibitors that would require active trans-
port for uptake.
Our objective was to characterise and assess BpDdl
as a potential antibacterial drug target and as part of
that assessment to initiate a search for new inhibitor
scaffolds. We report an efficient recombinant protein
production system, purification and crystallisation pro-
tocols, two high-resolution ligand-bound BpDdl struc-
tures (AMP and AMP+D-Ala-D-Ala) together with
comparisons with orthologues, the optimisation of two
enzymatic assays for the functional characterisation of
the enzyme and development of high throughput
(HTP) assays that were applied to selected compound
libraries. We used biolayer interferometry (BLI) and
enzymatic assays to assess the outcomes of the HTP
library screens and a computational assessment of the
BpDdl active site properties.
Results and Discussion
Overall subunit structure
Two high-resolution crystal structures have been deter-
mined, BpDdl:AMP and BpDdl:AMP:D-Ala-D-Ala,
with statistics in Table 1. Ddl is a member of the
ATP-grasp superfamily presents a characteristic and
highly conserved fold [16,25–28]. ATP-grasp proteins
contain three well-defined domains [16]. In the case of
Ddl, these are the N-terminal, central and C-terminal
domains (Fig. 1). BpDdl secondary structure comprises
10 a-helixes, one 310-helix, one p-helix and 12 b-
strands (Fig. 1A). The N-terminal segment presents an
a/b-domain whilst the central and C-terminal domains
comprise the ATP-grasp fold; two a/b-domains that
generate a narrow pocket for the ATP binding. The D-
Ala binding part of the active site is located in the C-
terminal domain. Two loops are implicated in the
binding of the co-factor and the substrate. The P-loop
(residues 149–159) is located in the central domain,
between b-strands 5 and 6, and interacts with the c-b
phosphates of ATP. The x-loop is located in the C-ter-
minal domain and presents a p-helix configuration
involving residues 198–222 (Fig. 1A). At several posi-
tions, gross structural differences are noted when com-
paring subunits of the two BpDdl structures (Fig. 1B).
The position of the central domains and several helices
on the N-terminal and C-terminal domains, that line
the active site, adopt different positions. The Ca com-
parison illustrates the notable conservation of these
structural changes in both BpDdl models (Fig. 1C).
Quaternary structure
In solution, at low concentrations, BpDdl behaves as a
monomer as indicated by SEC. Native-PAGE on a
more concentrated sample indicated monomer as well
as the presence of a higher molecular mass species,
possibly a dimer (Fig. 2). The crystal structures pre-
sent a dimer in the asymmetric unit with each subunit
aligned perpendicularly to the other (Fig. 1A). The
BpDdl dimer is formed by about 12–13% of the acces-
sible surface area (ASA) of a subunit, which involves
residues from a3, a4, a5 and the C-terminal region of
a8. Comparisons with structures from different organ-
isms (Table 2) indicate that the dimer arrangement is
shared (data not shown), and the ASA percentage
involved in the dimerisation, also called buried surface
area (BSA), is similar. These BSA values are lower
than expected for a surface with a high probability of
forming a multimeric assembly [29,30]. In contrast, the
P-value for the probability of having a similar
observed solvation free energy gain (DiG) in other sur-
face areas is lower than 0.5, indicating a higher level
of hydrophobicity than expected and it is likely this
property that drives oligomerisation [29]. Mycobac-
terium tuberculosis Ddl (MtDdl) [27] has a reduced
contact area, with no interactions involving residues
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on a3 and a8. Also, the P-value is higher for MtDdl
than the other structures. Ddl structures can be
grouped according to the additional number of amino
acids, compared to BpDdl, at the C-terminal end of
a10. When extra residues are present, a10 is elongated
towards the partner subunit and an increased number
of inter-subunit contacts assist dimer formation. This
is noted for Bacillus anthracis (BaDdl), Streptococ-
cus mutants (SmDdl) [31], Staphylococcus aureus
(SaDdl) [32], Coxiella burnetii (CbDdl) [27] and Xan-
thomonas oryzae (XoDdl) [12], where between 8 and 20
additional residues are observed. Table 2 also presents
the sequence identity shared with proteins of known
structure, which ranges from about 30% to 90%.
Despite a wide range of overall sequence identity com-
pared to BpDdl we note that residues contributing to
Table 1. Crystallographic statistics
Structure BpDdl:AMP
BpDdl:AMP:D-Ala-D-
Ala
PDB code 5NRH 5NRI
Space group P21 P21
Wavelength (A) 0.9174 0.9174
Unit cell dimensions 69.65, 61.15,
70.08
69.64, 61.13, 69.67
a, b, c (A), b (°) 90.17 90.31
Resolution rangea (A) 70.08–1.30 69.97–1.50
No. reflections 672 251 283 077
Unique reflections 141 049 90 609
Completeness (%) 97.6 (95.7) 96.6 (98.3)
Rmerge
b 0.04 (0.66) 0.05 (0.45)
CC1/2 0.99 (0.74) 0.99 (0.77)
Redundancy 4.8 3.1
<I/r(I)> 15.0 (2.1) 10.5 (2.1)
Wilson B (A2) 14.6 15.4
Rwork
c/Rfree
d 0.1459/0.1901 0.1325/0.2077
DPIe (A) 0.05 0.08
Bond lengths (A)/
angles (°)
0.018/2.247 0.027/2.583
Average B-factors
(A2)f
23.9 25.2
AMP average B-
factors (A2)
13.3 13.7
D-Ala—D-Ala average
B-factors (A2)
- 32.4
Protein residues 1412 1345
Water molecules 785 709
Metal ions 1 (Mg2+) 1 (Mg2+)
Ligands 7 (2 AMP, 2
SO24 , 3
ethylene glycol)
15 (2 AMP, 1 D-Ala-D-
Ala, 3 SO24 , 8
ethylene glycol, 1
poly-ethylene glycol)
Ramachandran analyses
Favoured regions
(%)
98 98
Allowed regions
(%)
99.8 99.8
aValues in parentheses refer to the highest resolution shell.
bRmerge = ∑hkl∑i|Ii(hkl)  <I(hkl)>|/∑hkl∑i Ii(hkl); where Ii(hkl) is the
intensity of the ith measurement of reflection hkl and <I(hkl)> is
the mean value of Ii(hkl) for all i measurements.
cRwork = ∑hkl||Fo|  |Fc||/∑|Fo|, where Fo is the observed structure
factor and Fc is the calculated structure factor.
dRfree is the same as Rwork except calculated with a subset, 5%, of
data that are excluded from the refinement calculations.
eDiffraction Precision Index. fProtein atoms.
Fig. 1. Cartoon representation of the BpDdl:AMP-2 structure and
structure comparisons. (A) Subunit A is coloured in blue, green and
orange, and subunit B in yellow. AMP is represented in sticks. a-
helixes and b-strands are numbered. 310 and p helixes are marked.
The N and C-termini are labelled as CT and NT. (B) Ca overlay of
subunit A (in green) and B (grey) from BpDdl:D-Ala-D-Ala. The green
sphere is Mg2+. (C) Values for r.m.s.d. (A) for Ca overlay of BpDdl
subunits. BpDdl:AMP-2 subunits are coloured in blue and BpDdl:D-
Ala-D-Ala in orange.
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dimer formation are well conserved, with Gly77,
Gly81, Val95, Ala99 and Asp103 present in 12–13
structures of the 14 analysed and three of these resi-
dues are also located near the active site binding pock-
ets (Gly77, Val95 and Asp103). Despite differences
elsewhere in the subunit–subunit interface, the dimer
arrangement is a recurrent feature in Ddl.
Co-factor and substrate-binding pockets
Co-factor and substrate-binding sites are identified in
Figs 1 and 3, the latter also showing electron density
associated with the ligands. Whilst the complete AMP
is well-ordered the N, Ca, Cb atoms of D-Ala1 are
not. The residues that contribute to the formation of
these binding sites are highly conserved in Ddl
sequences. Indeed, the ATP-binding site residues
(Lys104, Gly153, Glu184, Asp262, Glu275 and
Asn277) are also conserved within different functional
proteins from the ATP-grasp superfamily such as
acetyl-CoA carboxylase [16]. The recognition of ATP
involves residues from the central and C-terminal
domains. These include Lys104, Lys148 and Glu275
binding to the phosphate, and Glu184, Lys185, Ile187,
Glu192, Phe214 and Tyr215 that are involved in ade-
nosine recognition. In the case of D-Ala-D-Ala, the key
interacting residues are Tyr215, Tyr221, Asp277,
Arg260, Gly281, Ser286, Leu287 and also a Mg2+-
bound water molecule.
In the substrate-binding pocket, Lys220, Arg260,
Asp277 and Gly281 are strictly conserved and Leu287
in 90% of sequences. These are key residues for sub-
strate binding and catalysis according to the proposed
reaction mechanism [17,18]. Conservation is also noted
for Phe214, Tyr215 and Tyr221 (40–50% identity) with
other aromatic residues. These residues appear to be
involved in placing ATP and D-Ala in the correct posi-
tion for catalysis. In the ATP-binding pocket, Lys104,
Lys148, Glu184, Glu192 and Glu275 are conserved in
between 98% and 100% of the sequences highlighting
their importance to co-factor binding.
When BpDdl:AMP:D-Ala-D-Ala was compared with
other product and substrate-bound structures (from
EcDdl: PDB codes: 1IOV, 4C5B, 4C5C; from TtDdl:
2ZDH and 2ZDQ, including ADP+phosphinate,
ADP+D-Ala, ATP+D-Ala-D-Ala, ADP+D-Ala, ATP+D-
Ala respectively), differences in the substrate and pro-
duct binding were found (Fig. 4). The Ca overlay of
BpDdl:AMP:D-Ala-D-Ala (subunit A) with these
ligand-bound structures showed the location of D-Ala-
D-Ala, though similar, participates in different interac-
tions compared to previously characterised proteins.
Additionally, the relative position of the Mg2+ is dif-
ferent. In other Ddl structures (e.g. EcDdl, PDB code
4C5C), two Mg2+ ions interact with Asp262, Glu275
and c-b phosphates from ATP. However in BpDdl:
AMP:D-Ala-D-Ala only one Mg2+ is observed, interact-
ing with His70. The overall BpDdl:AMP:D-Ala-D-Ala
conformation presents a more open form than in other
structures, suggesting it is an intermediate conforma-
tion, but it cannot be distinguished if this corresponds
to a substrate binding or product release phase.
Conformational changes
Ligand-induced conformational changes can be
observed when comparing the AMP loaded structure
with an apo-form extracted from the PDB (Fig. 5).
Binding of AMP generates a more compressed confor-
mation where the central domain moves towards the
centre of the structure and the x-loop rotates and gen-
erates the active site pocket.
ATP binding therefore is likely to stabilise the x-
loop conformation enforcing interactions with Tyr215
to create a closed conformation. Phe214 is able to
interact with a hydrophobic area of the central
Fig. 2. SEC and Native-PAGE 3-12%
results. (A) SEC chromatogram for BpDdl.
The plot shows the equilibration curve
(blue) and BpDdl peak (orange dot). The
expected value for monomers is marked
with an arrow and dimer with a dashed
arrow. (B) Native-PAGE. Lane 1: Molecular
weight standards. Lane 2: 10 ng of BpDdl.
The arrow indicates the monomer and * the
expected value.
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domain, and Glu213 with Lys160 to assist closing the
ATP-binding pocket. The conformational change in
the central domain involves a movement/shift of a7 of
about 12.5 and 7.6 A for a6 (average distances from
both subunits) favoured by the AMP and x-loop inter-
actions. Additionally, the conformation of the P-loop
is stabilised by AMP interactions, the x-loop and the
N-terminal domain residue. In apo-BpDdl, the P-loop
Table 2. Comparison of BpDdl with orthologues extracted from the PDB. The first section of the table shows, the percentage of the
protein sequence similarity (ID), r.m.s.d. values of the Ca overlay of BpDdl:AMP subunit B and a selected Ddl monomer, and the percentage
of residues in the dimer interface (ResDimer) that are conserved and semi-conserved (in brackets). The second part includes the ASA, BSA
values for each subunit (indicated in the subscript), and P-values (probability of the specificity of the interface). BSA is noted as A2 and %.
(*) Overlay performed between subunits B from BpDdl:AMP and BpDdl:AMP:D-Ala-D-Ala. B. anthracis (Ba), B. ambifaria (Bam),
B. pseudomallei (Bp), B. xenovorans (Bx), C. burneii (Cb), E. coli (Ec), H. pylori (Hp), M. tuberculosis (Mt), S. aureus (Sa), S. mutants (Sm),
Thermus thermophilus (Tt), T. caldophilus (Tc), X. oryzae (Xo) and Y. pestis (Yp)
Organism Bp Bam Bx Yp Ec Tt Tc
PDB BpDdl-AMP 4EG0 4EGJ 3V4Z 4C5C 2YZG 2FB9
ID (%) – 92 89 49 48 31 31
r.m.s.d. (A) 0.12* 0.39 0.63 1.28 1.92 1.84 1.85
ResDimer (%) – 100 100 45 (21) 45 (28) 41 (17) 41 (17)
ASAA (A
2) 13 896 12 529 12 231 13 489 13 186 14 918 15 331
BSAA (A
2) 1793 1287 1089 1331 1666 1372 1368
BSAA (%) 13 10 9 10 13 9 9
P-valueA 0.007 0.060 0.090 0.022 0.008 0.018 0.044
ASAB (A
2) 13 163 12 823 11 431 13 601 13 109 13 983 15 331
BSAB (A
2) 1540 1309 1089 1061 1496 1372 1368
BSAB (%) 12 10 10 8 11 10 9
P-valueB 0.014 0.064 0.094 0.008 0.010 0.018 0.048
Organism Xo Ba Sa Cb Sm Mt Hp
PDB 4ME6 3R23 2I87 3TQT 3K3P 3LWB 2PVP
ID (%) 30 34 25 24 28 30 23
r.m.s.d. (A) 1.54 1.60 1.73 1.95 2.33 1.63 3.76
ResDimer (%) 38 (21) 24 (28) 24 (28) 24 (24) 24 (21) 17 (14) 17 (34)
ASAA (A
2) 16 009 14 940 16 632 16 012 14 731 14 807 16 997
BSAA (A
2) 1800 1433 2329 2294 1557 954 1454
BSAA (%) 11 10 14 14 11 6 9
P-valueA 0.013 0.046 0.176 0.021 0.169 0.382 0.158
ASAB (A
2) 16 041 14 842 16 879 15 532 14 669 13 426 16 365
BSAB (A
2) 1800 1281 2325 2294 1557 959 1454
BSAB (%) 11 9 14 15 11 7 9
P-valueB 0.011 0.041 0.083 0.003 0.187 0.333 0.091
Fig. 3. ATP and D-Ala-D-Ala binding pockets.
(A) ATP-binding pocket. AMP is represented
as dark grey sticks and the 2Fo-Fc map (5.0
r) is shown as a green mesh. (B) D-Ala
binding pocket. The dark grey sticks
represent D-Ala-D-Ala. Red circles indicate
atoms with zero occupancy. The x-loop is
represented as a yellow cartoon. The Fo-Fc
map is represented as a green mesh (2.3
r). Hydrogen bond interactions are
indicated with black lines.
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is disordered and not included in the model but in the
AMP-bound structures this loop is ordered with an
average B-factor of 36.7 A2 (the overall average B-fac-
tor value is 23.9 A2). This higher B-value suggests a
greater degree of flexibility in the loop.
There are apo and ligand-bound structures for
SaDdl (2I8C, 2I80, apo: 2I87) [32] and TtDdl (2YZM,
2YZN, 2ZDH, 2ZDG, 2ZDQ, apo; 2YZG). In both
cases, the conformational changes noted when compar-
ing different states do not appear as pronounced as in
BpDdl. Movement of the TtDdl central domains
involves an a7 translation of 4.7 A, whereas no differ-
ences in SaDdl are observed. This tends to suggest
that the conformational changes are distinct in differ-
ent organisms. As indicated in ESC library screening
in Results and Discussion, purified BpDdl contained
AMP and we were unable to obtain an apo-BpDdl
crystal form. With this in mind, electron density maps
of the apo-BpDdl, SaDdl and TtDdl structures were
inspected to check for missed co-factors but in all
three there was no evidence of anything bound in the
ATP pockets.
A comparison of the electrostatic surfaces in and
around the active sites of apo-BpDdl and BpDdl:AMP
reveals significant differences (Fig. 6). The D-Ala
pocket is more electropositive in the AMP-bound
structure. Therefore, at pH 7.5, D-Ala (pI = 6.01)
would preferably bind to the BpDdl:AMP conforma-
tion over the apo-form. This suggests that the D-Ala
pocket is formed after the x-loop conformational
change. The residues involved in determining the elec-
trostatic properties of the different conformations
(Glu22, Asp262, Glu275 and Asn277 in apo-BpDdl,
and His70, Arg260 and Asn277 in BpDdl:AMP) are
highly conserved. Also, as described previously, His70,
Arg260 and Asn277 are key amino acids for Ddl catal-
ysis. This is consistent with the hypothesis that the
generation of a favourable environment for catalysis is
dependent on ATP binding, in agreement with the
sequential ordered mechanism previously characterised
[17,18] where ATP is the first component to bind Ddl.
Biochemical characterisation
Enzyme kinetics
Enzyme activity was investigated using a coupled spec-
trophotometric assay and a BIOMOL Green assay at
Fig. 4. Ca Overlay of BpDdl:D-Ala—D-Ala
and EcDdl (4C5C). BpDdl:D-Ala—D-Ala is
coloured in grey EcDdl in yellow. Ligands
are represented as sticks. Mg2+ are
represented as spheres coloured in green
(BpDdl:D-Ala—D-Ala) or yellow (EcDdl).
Fig. 5. Conformational change. (A) Ribbon
diagram of the superposition of the apo-
BpDdl (4EGQ in dark red) and BpDdl:AMP-2
(yellow). AMP is represented with sticks.
(B) Residues implicated in co-factor binding.
Blue indicates the N-terminal domain,
orange the central domain and green the
C-terminal domain.
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pH 7.5 and 8 (Table 3). Using the coupled assay, inhi-
bition of the enzyme activity was observed at high
concentrations of ATP and Ki,ATP was also deter-
mined. In the BIOMOL Green assay, high ATP con-
centrations decrease the signal-to-noise ratio due to
nonenzymatic hydrolysis and consequently, ATP con-
centrations did not exceed 1 mM. Nevertheless the Ki,
ATP could not be accurately determined with the BIO-
MOL assay. The values for Km2 were consistent
between the coupled and the BIOMOL assays. Com-
paring the Km values with other Ddl enzymes, we note
more similarity between BpDdl and MtDdl or EcDdl
than Yersinia pestis Ddl or HpDdl (Table 1). Indeed,
HpDdl seems to be the least related Ddl, not only dis-
playing a lower sequence identity but also different
kinetic parameters.
We showed that our BpDdl samples had AMP-
bound, so the KATP determination is compromised.
No information about the presence of AMP or similar
compounds in HpDdl, EcDdl and MtDdl has been
reported. Purification of MtDdl [17] and HpDdl [26]
was carried out using nickel-affinity columns whereas
EcDdl used ion exchange [20,33]. It is possible that
MtDdl and HpDdl also co-purified with the co-factor
as similar protocols to those we used for BpDdl were
employed; however direct confirmation would have to
be sought.
The pH optimum for BpDdl was determined. Differ-
ences in the activity due to the change in the pH are
observed in the Km2 and the Vmax determinations. At a
lower pH there is an increase of 1.2 times in the Km2
and 1.7 times decrease in the Vmax. To further explore
this, activity was measured over a pH range of 5.1–
9.5. Regarding this, a test at different pH values has
been carried out (Fig. 7). The peak of the maximum
activity is observed at pH 8 (100% relative activity)
and the activity decreases around 1.7 times at pH 7.5
(56% relative activity). This is consistent with the
results from the Km experiments.
Determination of the Ki and the mechanism of inhi-
bition for DCS were assessed (Fig. 8). DCS appears to
be a competitive inhibitor of substrate with a Ki,DCS
value of 100 lM. At the highest DCS concentration
tested, 1 mM, a different Vmax was observed what may
Fig. 6. Electrostatic surface. (A) apo-BpDdl
(4EGQ) and (B) BpDdl:AMP-2 structures.
Orange arrows indicate the D-Ala pocket
location and black arrows the ATP pocket.
Dashed arrows indicate ATP pocket is
closed and D-Ala pocket is formed. On the
right side of each surface an enlargement
of the D-Ala pockets are shown and amino
acids marked.
Table 3. Kinetic parameters for Ddl. Km values for two D-Ala and ATP, the Ki for ATP and the Vmax of the reaction
Detection method pH Km1 (mM) Km2 (mM) KATP (mM) Ki,ATP (mM) Vmax (nmol NAD
+min1)
Coupled 8 0.37  0.085 4.19  0.71 0.07  0.01 3.16  0.59 21.85  0.98
Coupled 7.5 0.35  0.03 5.12  1.09 – – 12.92  1.38
Biomol 8 – 4.9 0.13 – –
BiomolTCEP/Tween 8
a – 3.2 0.2 – –
Biomol200 lM ATP 8
b – 2.3 – – –
BiomolTCEP/Tween 7.5
a – 5.4 0.27 – –
HpDdl [26] 8 1.89 627c 0.000087 – –
EcDdl [21] 7.8 0.0012 1.13 0.049 – –
MtDdl [18] 8 0.075  0.01 3.6  0.6 0.31  0.05 – –
YpDdl [14] 7.8 0.006 0.07 3.2 – –
aIn the presence of 1 mM TCEP and 0.01% (w/v) Tween-20.
bKm2 in the presence of 200 lM ATP instead of 500 lM ATP.
cMaximum D-Ala concentration tested. (–) Not determined.
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indicate that the dynamics of binding changes. DCS
could be binding both D-Ala pockets and so
display different binding behaviour. For MtDdl (Ki,
DSC of 25 lM) and EcDdl (Ki,CDS of 185 lM), it was
reported that slow binding of DCS occurs [19] but not
at a high concentration (1000 lM). This DCS concen-
tration dependent behaviour appears to also apply to
BpDdl.
Quantification of AMP
Characterisation of structures derived from crystals
grown in the presence of different ligands, or none,
revealed all had AMP-bound. This, we presume is
derived from the expression host and we decided to
quantify the level of AMP in the purified sample.
Denatured and folded samples were compared.
Firstly, controls BaKynB, BaKynB in the presence
of 2 lM AMP and BpDdl itself were denaturated using
(a) pH extremes, (b) an elevated temperature and (c)
chymotrypsin digestion. The experimental and
expected results are shown in Fig. 9. The negative con-
trol (in the absence of protein and AMP) and positive
control (10 lM AMP in the absence of protein) results
were similar to expected values. BaKynB likewise, con-
firmed there is no AMP-bound [34]. The BaKynB data
indicate that the different sample treatments are not
interfering with the AMP-glo assay. The results for
BpDdl demonstrate the sample has been co-purified
with AMP. The presence of AMP without pretreat-
ment of BpDdl indicates there is some free material in
the protein solution (around 0.4 lM) probably due to
AMP exchange/release. The sample treated with chy-
motrypsin presents an AMP concentration of about
2 lM that indicates 1.6 lM (approximately 15 nmol)
AMP remains bound to BpDdl. Taking into account
that the concentration of BpDdl is 25 mgmL1 (about
Fig. 7. Effect of pH on enzyme activity. The relative activity is set
to 100% at maximum level, at pH 8.
Fig. 8. DCS Ki determination. (A) Double reciprocal plot for the DCS inhibition and the corresponding equation for competitive inhibition. (B)
Secondary representation for inhibitory data. Plot of the slopes from the reciprocal plot against the concentration of DCS. From the
equation of the slope of this line the Ki,DCS can be determined as shown in the accompanying equation. V, reaction velocity (nmolmin1);
Km, Michaelis–Menten constant (M); Vmax, maximum velocity of the reaction (nmolmin1); [S], substrate concentration (M); [I], inhibitor
concentration; Ki, inhibitory constant.
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20 nmol), then the ratio AMP:BpDdl suggests almost
full occupancy of BpDdl by the monophosphate. This
is consistent with the structural data that show one,
well-ordered AMP per BpDdl subunit.
The presence of AMP in the purified enzyme, pre-
sumably acquired from the bacterial expression system
has implications for our analyses. The KATP determi-
nation and the compound screens therefore have been
done mainly with the binary complex BpDdl:AMP
instead of apo-BpDdl. Additionally, during the spec-
trophotometric assay, a retarded phase was observed
at the onset of the reaction (Fig. 10). This could be
due to diffusion of AMP that has to first occur prior
to ATP loading. Also, the fragment screen using BLI
was carried out with the closed BpDdl conformation
and that might explain why a relatively low ATP-bind-
ing signal was measured.
An apo-BpDdl structure (PDB code 4EGQ) has
been determined by the Seattle Structural Genomics
Center for Infectious Disease. Electron and difference
density maps in the ATP-binding sites were inspected
to ascertain if a ligand might be present. There were
no significant features so we conclude this is a
bone fide apo-BpDdl form. It is unclear why in our
structures AMP is present and this may be due to dif-
ferent purification or crystallisation protocols. The
PDB entry stipulates that the apo-form crystal was
grown at a basic pH (0.1 M CHES pH 9.5, 1 M Na+-
K+ tartrate and 0.2 M Li2SO4) whereas the crystals
obtained in our work were obtained at pH 5.5. There
are no details of the apo-form purification. Whilst it is
not uncommon for a purified protein to acquire
ligands during recombinant protein purification as
exemplified by human PPAR-b/d binding endogenous
fatty acids of E. coli [35], it is intriguing in this case.
We speculate that this might be indicative of a mecha-
nism whereby the levels of AMP:ATP could be net-
worked to the control exercised by the second
messenger cyclic di-AMP to regulate peptidoglycan
biosynthesis [36]. The role of AMP and derivatives is
coming under increased scrutiny in this aspect [37].
Compound library screens
We screened three compound libraries. BLI was used
in conjunction with a fragment library whilst the mala-
chite green-based assay was applied to the ESC and
small diversity set libraries.
BLI: Fragment library screen
BpDdl was interrogated with a fragment library of
around 700 compounds, using a BLI binding assay. A
total of 11 hits were selected for a secondary inhibition
assay at 500 lM. A single compound (Fig. 11) gave
enzyme inhibition with a Ki value of 10 mM. Attempts
to obtain a structure of the hit in complex with the
enzyme by co-crystallisation failed.
Fig. 9. Quantification of AMP. Neg: is the
negative control (without enzyme, without
AMP). Pos: is the positive control from the
standard curve (without enzyme with 10 lM
AMP). KynB: is the BaKynB sample. WT:
means no pretreatment is performed. DT
and DpH: indicates variations in the
temperature or pH were carried out. Ch:
indicates digestion with chymotrypsin was
used and + is used when 2 lM AMP was
added. The error bars correspond to the SD
derived from three experiments.
Fig. 10. Spectrophotometric assay raw data. A plot of absorbance
(340 nm) against time (s). The circle indicates a retarded phase of
the reaction.
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ESC library screening
The optimised HTP assay had a Z0 score of 0.8 and a
signal-to-noise ratio of 5 after 80 min of reaction. Ini-
tially, the experiments were run in the absence of
TCEP and Tween-20. To target the substrate and co-
factor binding sites, a concentration of D-Ala and ATP
close to the Km values was used. A library of 6775
compounds, comprising well-known drugs, and, for
control purposes, known aggregators, was tested. A
total of 74 hits were selected and re-tested using the
BIOMOL Green assay. Results showed no interference
by any of the compounds but that 61 appeared to be
false positives leaving 13 compounds for further inves-
tigation. The dose–response experiment for the hits
was performed in the presence of 1 mM TCEP and
0.01% (w/v) Tween-20 and no inhibition was
observed. Thus the redox environment may affect the
stability of the compounds and/or induce aggregation.
Indeed, inspection of the chemical structures suggested
they could also be aggregators [38] and this was fur-
ther supported by the dose–response profile from one
of the compounds (SAM001247071, Fig. 12), which is
characteristic of this issue [39]. Although our assay
appears to be reliable no useful hits were obtained.
DDU small diversity set screening
Due to the high similarity of the ATP-binding pockets
between different functional proteins (glutathione syn-
thetase [40], ATP-citrate lyase [41], succinyl-CoA ligase
[42] and kinases [43]), targeting this pocket might
result in inhibition of human enzymes with toxic side
effects. To avoid this, the inhibitor search was focused
on obtaining new inhibitors targeting the D-Ala bind-
ing pocket. The DDU diversity set screen was selected
to inform on this part of the active site. A new optimi-
sation of the HTP assay was carried out to establish
screening conditions to target this pocket. The reaction
was linear for 20 min, the signal-to-noise ratio 6 and
the Z0 score 0.8–0.9. From the 15 667 compounds
tested, four hits were selected on the basis of a 30%
inhibitory effect. However, the follow-up dose–re-
sponse experiment identified them as false positives.
Experimental procedures
Recombinant protein production
An oligonucleotide encoding BpDdl (Unitprot code: Q63QJ9,
protein mass 33 kDa) was purchased from GeneWiz (Takeley,
Essex, UK) and inserted into a modified pET15b vector
(Novagen, Madison, WI, USA), that adds an N-terminal hex-
ahistidine tag followed by a tobacco etch virus (TEV) protease
cleavage site before the resulting target protein. The restriction
enzymes used were NdeI (at the 30 DNA end) and BamHI (50
end). The integrity of the construct was confirmed by sequenc-
ing. Recombinant protein production was achieved with BL21
(DE3) cells, 1 mM IPTG (final concentration) for induction
and incubating overnight (O/N) at 20 °C. Purification
involved use of metal ion affinity chromatography with a
Ni2+-NTA column (GE Healthcare, Chicago, IL, USA) using
buffer A (20 mM Tris-HCl pH 7.4, 200 mM NaCl, 5 mM
MgCl2) for sample loading and buffer B (20 mM Tris-HCl pH
7.4, 200 mM NaCl, 5 mM MgCl2, 800 mM imidazole) for elu-
tion. The hexahistidine tag was cleaved, during dialysis back
into buffer A, using 1 mg of TEV protease per 10 mg of
BpDdl, incubated O/N at 4 °C. A second round of affinity
chromatography with a Ni2+-NTA column removed the tag
and the TEV protease, itself carrying a hexahistidine tag, and
fractions carrying the purified protein were pooled. Protein
purity and molecular weight were assessed by SDS/PAGE.
Protein concentration was determined using the theoretical
molar extinction coefficient e(BpDdl) = 27 515 M1cm1 as
calculated in PROTPARAM [44]. Quaternary structure was inves-
tigated using native-PAGE (Novex, ThermoFisher Scientific,
Waltham, MA, USA) and size-exclusion chromatography
(SEC) using buffer A and the HiLoad 16/60 superdex 200
prep grade column (GE Healthcare).
Crystallisation
The protein sample was concentrated to 25 mgmL1 in
buffer A. Initially, thin needle shaped crystals grew in sit-
ting drops plates at 18 °C after incubating the protein (at
different protein : reservoir ratios) with a reservoir contain-
ing 0.2 M Li2SO4, 0.1 M Bis-Tris pH 5.5 and 25% (w/v)
PEG 3350. These crystals were crushed to provide micro-
seeds. Hanging drops were set up using a protein : reser-
voir ratio of 1 : 1 (in a final volume of 4 lL) plus 0.5 lL
of crystal seeds. Crystals grew at 18 °C under various con-
ditions: 0.05–0.3 M Li2SO4, 0.1 M Bis-Tris pH 5.5 and 15–
30% (w/v) PEG 3350. Co-crystallisation with different
ligand combinations was attempted using BpDdl incubated
for 30 min on ice in the presence of different ligandFig. 11. The structure of one compound identified in the fragment
screen.
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combinations (e.g. ATP, DCS, D-Ala+ADP, D-Ala-D-
Ala+AMP, DCS+AMP, DCS+AMPPNP). Numerous crys-
tals were analysed but only two structures are reported, a
binary complex with AMP and a ternary complex with D-
Ala-D-Ala+AMP. In all other cases only AMP was
observed in the active site and this will be discussed further
below.
Diffraction, data collection and structural
analyses
Optimised crystals, grown in the presence of ATP, were
tested in-house using a M007HF X-ray generator with a
Saturn 944HG+ CCD detector (Rigaku-Americas, Wood-
lands, TX, USA) and subsequently used to record a 2.0 A
resolution data set on ESRF beamline BM30-A. The data
were indexed and integrated using XDS [45], then scaled and
analysed using AIMLESS [46]. The Matthews coefficient (Vm
of 2.27 A3Da1 with bulk solvent of about 50%) suggested
two molecules in the asymmetric unit. Two subunits were
positioned with PHASERMR [47] using only the protein com-
ponents of the 2.2 A resolution apo-BpDdl structure (PDB
code 4EGQ, subunit A). Rigid body refinement followed
by cycles of restrained refinement using REFMAC [48], elec-
tron and difference density map inspections, and model
manipulations were made with COOT [49]. AMP, not ATP,
was observed in the active site and the end result was a
2.0 A resolution structure of this binary complex. Other
crystals, of putative apo-enzyme and grown in the presence
of different ligands provided 13 data sets on Diamond
beamline I04-1. Data were processed using XDSgui and
IMOLSFLM [50], and scaled and merged with AIMLESS. All
crystals were isomorphous with the initial structure. These
data produced two structures. In one case, that of a crystal
obtained in the presence of ADP and D-Ala, data extending
to 1.3 A resolution were recorded and molecular replace-
ment was performed with the refined subunit A from the
binary complex. This structure only showed AMP-bound in
the active site and hence, due to a superior resolution,
supersedes the first; this structure is BpDdl:AMP. A 1.5 A
resolution structure of a ternary complex of BpDdl:AMP:
D-Ala-D-Ala was the second structure. This was refined
starting from the BpDdl:AMP model. Tight, noncrystallo-
graphic symmetry (NCS) restraints were employed at the
onset of the refinements and these were released once sol-
vents and ligands were included. Side-chain rotamers, water
molecules and ligands, for example, ethylene glycol, were
added when the protein models were completed and then ani-
sotropic thermal parameters were included in the model. In
the case of the ternary complex, a difference Fourier map
suggested the presence of D-Ala-D-Ala. A model with full
occupancy for the complete ligand resulted in negative differ-
ence density at the N-terminus of the dipeptide. However, if
only the second D-Ala was refined, positive difference density
was observed. We conclude that the first D-Ala (D-Ala1) is
not fully ordered and although included in the model we
assigned zero occupancy. A Mg2+ ion is present near His70
(subunit A). Two strong difference density features, in
BpDdl:AMP (near residues 293 from subunit A, 221 from
subunit B) were interpreted as SO24 ions. Three such exam-
ples were noted in BpDdl:AMP: D-Ala-D-Ala (near residues
293 from subunit A, 221 and 290 from subunit B). The sul-
phates near residue 221 occupy the D-Ala binding pocket.
Refinement was concluded when no improvements resulted
for Rfree and Rwork values, when density maps indicated no
further changes were justified and that satisfactory model
geometry was obtained. For the other data sets, omit maps
were inspected after some refinement and AMP was noted in
all structures, irrespective of the ligands that had been added
or when an apo-structure was sought. This indicated that
AMP might be present in the protein solution, a point we
had to investigate (see below).
Model analyses and informatics
MOLPROBITY [51] was used to assess model geometry. Sec-
ondary structure was inspected using DSSP [30], the dimer
interface was analysed using PISA [29,52] and MOLSOFT ICM
(www.molsoft.com), and B-factors analysed using Baverage
from the CCP4I suite. Figures were prepared using ALINE
[53], PYMOL (www.pymol.org) and MOLSOFT ICM. The DALI
server [54] was used for comparative purposes whilst elec-
trostatic surfaces and properties of the enzyme active site
were determined using MOLSOFT ICM.
%
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Fig. 12. ELF hit SAM001247071 dose–
response curve. (A) Dose–response curve
of compound SAM001247071. (B)
Compound structure.
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A comparison of Ddl sequences was carried out. First, a
search for relevant sequences in UniProt (www.uniprot.org)
was conducted. The identified sequences were grouped by
50% identity and aligned using CLUSTAL OMEGA [55] with
group representatives (based on 588 sequences).
Enzymatic assays
A coupled spectrophotometric assay was initially optimised
for characterising the enzyme. To support the HTP screen-
ing of compound libraries, a malachite green-based assay
was developed.
A coupled spectrophotometric assay
Km determination
The activity of BpDdl was measured using a spectrophoto-
metric assay [17]. The assay buffer contained 100 mM Tris-
HCl pH 8, 100 mM KCl, 10 mM MgCl2, 2.5 mM phospho-
enolpyruvate (PEP), 0.4 mM NADH, 5 lLmL1 phospho-
glycerate kinase/lactate dehydrogenase (PK/LDH) (Merck
& Co, Kenilworth, NJ, USA) and 30 lM BpDdl. Addition-
ally, to determine Km for D-Ala and ATP, 500 lM ATP
and variable concentrations of D-Ala (0.1, 0.3, 0.5, 0.7, 1,
1.5, 2, 2.5, 3, 5, 10, 20 and 100 mM) or 10 mM D-Ala and
variable concentrations of ATP (0.1, 0.2, 0.5, 1.2 and
3 mM) were added respectively. Ten times (109) concen-
trated D-Ala/ATP stocks were prepared for each assay so
the volume added was constant. The final reaction volume
was 100 lL, and the reaction started by adding the enzyme.
All components were incubated for 30 min at 30 °C and
then the assay was performed in triplicate. Negative con-
trols included the master mix with BpDdl and without sub-
strate, and the master mix without BpDdl and with D-Ala/
ATP. No decrease in absorbance was detected in the nega-
tive controls during the assay period. The positive control
was the PK/LDH combination and instead of ATP,
0.4 mM ADP was added. Initial velocities were obtained by
measuring the steady-state rate for 60 s and determination
of the Km values [Km1(D-Ala), Km2(D-Ala), Km(ATP)] was
carried out as previously described [17]. Inhibition of the
enzyme activity at high ATP concentrations was observed,
and the Ki,ATP calculation was carried out with GRAPHPAD
(www.graphpad.com).
BpDdl inhibition
Inhibition experiments were performed in the presence of
different inhibitor concentrations to determine Km2(D-Ala).
In the case of DCS the concentrations used were 100, 200,
250, 300, 500 and 1000 lM. Stocks (109) for each inhibitor
concentration were prepared. Each Ki determination was
conducted for about 12 h. To check for time-dependent
loss of BpDdl activity, an assay without inhibitors was
performed before and after the inhibition studies. Ki calcu-
lations were performed using double reciprocal plots [17].
To check for inhibition of any of the coupled enzymes, a
cross-validation assay was performed. The assay buffer in
this case contained 100 mM Tris-HCl pH 8, 100 mM KCl,
10 mM MgCl2, 2.5 mM PEP, 0.4 mM NADH, 5 lLmL1
PK/LDH mixture and 0.5 mM ADP. Concentrations of 0.5
and 10 mM DCS (from stock 1 M) and a positive control
(without inhibitor) were tested. No inhibition was detected.
A potential inhibitor was identified (see below) and the Ki
determination was carried out as for DCS using final con-
centrations of 200, 500, 2000 and 5000 lM.
The pH profile of BpDdl activity
The reaction mixture contained 100 mM of the selected buf-
fer, 10 mM KCl, 10 mM MgCl2, 2.5 mM PEP, 0.4 mM
NADH, 5 lLmL1 PK/LDH mix, 0.5 mM ATP, 10 mM D-
Ala and 20 lM BpDdl (added to start the reaction). The
buffers used are: Bis-tris pH 5.5, Tricine pH 5.1, MES pH
6.0, HEPES pH 7.5, Tris-HCl pH 7.5, Tris-HCl pH 8.0,
Tris-HCl pH 8.5, HEPES pH 8.5, BICINE pH 9.0 and
CHES pH 9.5. The maximum reaction rate was used to
define 100% activity.
Malachite green-based assay
Km determination
The release of phosphate after ATP hydrolysis can be mea-
sured using malachite green (BIOMOL green, ENZO life
sciences, Farmingdale, NY, USA). This set of experiments
and a compound library screen (see ESC library screen using
the malachite green-based assay in Experimental procedures)
were carried out at the European Screening Centre (ESC,
Newhouse, UK). The assays were run at room temperature
in a final volume of 30 lL, in clear bottom 384 well plates
(Greiner, Kremsmunster, Austria). The assay buffer to
determine the Km2(D-Ala) and Km(ATP) contained 100 mM
Tris-HCl pH 8, 10 mM KCl, 10 mM MgCl2, 0.4 nM BpDdl,
variable concentrations of D-Ala (serial 1/4 dilutions from
top concentration of 10 mM) or ATP (serial 1/4 dilutions
from top concentration of 0.5 mM) and 0.5 mM ATP or
10 mM D-Ala respectively. The time points used in these
experiments were as follows: 10 s, 30 s, 1, 1.5, 2, 3, 5, 7, 10,
15 and 20 min. To avoid nonspecific ATP hydrolysis due to
the low pH of the BIOMOL green reagents, tri-sodium
citrate was added to each reaction at a final concentration of
0.65% (w/v). Each experiment included four replicates.
Absorbance was recorded at 620 nm using a PerkinElmer
EnVision plate reader (PerkinElmer, Waltham, MA, USA).
For the calculations of D-Ala Km, only Km2 was taken into
account and data were analysed with the Michaelis–Menten
equation. High ATP concentrations are incompatible with
the BIOMOL Green assay hence enzyme inhibition by this
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compound was not a factor and KATP was determined using
the Michaelis–Menten equation. Regarding the Km2(D-Ala)
and Km(ATP) results, the chosen HTP assay conditions were
as follows: 100 mM Tris-HCl pH 8, 10 mM KCl, 10 mM
MgCl2, 0.4 nM BpDdl, 200 lM ATP and 5 mM D-Ala.
To determine whether the assay was linear under the cho-
sen assay conditions, a time course experiment was carried
out. A total of 24 reactions were started at time points
2.5 min apart during 90 min, and eight replicates included.
Additionally, the same experiment was done in the absence
of enzyme. These results were used to determine the Z0 score
(Eqn 1) and the signal-to-noise ratio of the experiment.
Z0 ¼ 1 3ðSDmax þ SDminÞ
mean (max)mean (min) ; ð1Þ
SD = standard deviation, max = maximum signal,
min = minimum signal.
Determination of DMSO tolerance and D-cycloserine
IC50
Using the HTP assay conditions, a dose–response experi-
ment was performed using variable concentrations of
DMSO (from 0% to 27%) or DCS (0–300 lM). A 2% inhi-
bition of enzyme activity was noted at 6% DMSO.
Compound library screens
Fragment library screen using BLI
A fragment library from the Drug Discovery Unit (DDU,
University of Dundee) was screened using an OctetRED384
(ForteBio-Molecular Devices, Fremont, CA, USA). The
protein was immobilised on hexahistidine tag high affinity
sensors (ForteBio), and the experiment carried out in black
plates (Greiner). We used TEV protease as a control and
to identify promiscuous binders, and ATP as the control
ligand. During the assay performance, we noticed a low
binding signal (lower than 0.1 nm) in the presence of ATP.
Selected hits were tested for enzyme inhibition using the
coupled enzymatic assay at a fixed concentration of
500 lM, in the presence of 2 mM D-Ala. One compound
with an inhibition effect greater than 20% was followed up
for Ki determination.
ESC library screen using the malachite green-based
assay
A small selection of compounds from the BioAscent com-
pound cloud and the NCC library of drug compounds from
the NIH were tested at a concentration of 10 lM. Each
screening plate included positive (normal reaction without
compounds added) and negative controls (without enzyme).
Compounds were dispensed using a Labcyte Echo acoustic
dispenser. The assay was carried out using the HTP condi-
tions and allowed to proceed for 1 h before stopping the
reaction by adding BIOMOL green. Data were analysed
using ActivityBase XE (www.idbs.com). A compound was
considered a hit when the normalised percentage effect was
higher than the median plus three times the standard devia-
tion. The final DMSO concentration during screening
reached 0.075% so the assay has not been compromised.
Selected hits were re-tested using the HTP assay conditions
in the presence and absence of enzyme with a final concen-
tration of 20 lM to filter false positives. Compounds inhibit-
ing more than 30% of BpDdl activity were selected for IC50
determination. The dose–response experiment was carried
out using the same conditions and in the presence or absence
of 0.01% (w/v) Tween-20 and 1 mM TCEP. Data were anal-
ysed using ActivityBase XE and Microsoft EXCEL.
Small diversity set screen using the malachite
green-based assay
A small diversity set library was screened under HTP assay
conditions modified to target the D-Ala pocket, at pH 7.5,
and including 0.01% (w/v) Tween-20 and 1 mM TCEP in
the assay buffer. Consequently, further assay optimisation
was required. Km2(D-Ala) and Km(ATP) at pH 7.5 were
determined as described before using 1 nM BpDdl. The time
course experiment was performed with 3, 2 and 1 mM D-
Ala and 500 lM ATP. The compound set was used at a
final concentration of 30 lM. The reaction was carried out
with 1 mM D-Ala and 0.5 mM ATP, and incubated for
12 min then absorbance was measured using a PHERAstar
(BMG Labtech, Ortenberg, Germany). Data were analysed
using ActivityBase XE and Microsoft EXCEL and any
compound providing 30% inhibition was considered a hit.
Validation of hits was performed by dose–response experi-
ments using different concentrations (1/10 dilutions starting
at 100 lM) in duplicate.
AMP detection
The crystallographic analyses revealed the presence of AMP-
bound to the protein even when no nucleotide was added to
the sample. Therefore, the AMP-Glo kit from Promega
(Madison, WI, USA) was used to quantify the presence of
AMP in the purified BpDdl. The reaction was performed in
a 96-well white plate (Greiner), using 25 lL of sample, in
triplicate. The signal was measured with a FLUOstar
OPTIMA microplate reader (BMG Labtech). The control
protein, selected because it does not bind AMP/ADP/ATP,
was an amidase called BaKynB [34]. Samples were denatu-
rated before AMP quantification using three different treat-
ments. These included heating (20 min at 100 °C prior to
the assay performance), exposure to extreme pH (2 min
incubation at pH 2, then pH 10, then 7) and digestion with
chymotrypsin. The samples used were BpDdl, BaKynB and
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BaKynB in the presence of 2 lM AMP (BaKynB-AMP) as a
control. Chymotrypsin was added to a final ratio chy-
motrypsin : sample of 1 : 20 and the mixtures incubated O/
N at 25 °C. Then, the samples were filtered using an Amicon
ULTRA 3K concentrator (Merck & Co). The protein con-
centration was 4 mgmL1 for BaKynB and 25 mgmL1
for BpDdl. Data are presented in Fig. 9.
Conclusions
We set out to assess, and potentially validate, BpDdl as
a target for the development of the new antibacterial
drugs for B. pseudomallei. Two high-resolution crystal
structures of BpDdl in complex with AMP and AMP+
D-Ala-D-Ala were obtained. Comparative studies indi-
cate aspects of Ddl that are well conserved allow us to
describe conformational differences that result from
ligand binding. The BpDdl structures provided tem-
plates for a computational druggability assessment, but
also identified that the enzyme was retaining AMP dur-
ing isolation. This was confirmed using an AMP detec-
tion assay. The co-purification with AMP suggests that
we have assayed a binary complex not the apo-enzyme.
This had not been reported previously and might also
apply in other Ddl studies. The BpDdl activity was
measured using two different enzyme assays and
showed similar kinetic parameters to two other Ddl
enzymes but different from a third. We noted a retarded
phase during assay that was probably due to the pres-
ence of AMP which first has to vacate the co-factor
binding site prior to catalysis.
High-throughput binding and enzymatic assays were
developed to conduct compound library screens.
Despite screening more than 22 500 compounds, we
did not identify any good starting points for further
study. Whilst our study was underway, AstraZeneca
reported a larger compound library screen for Strepto-
coccus mutans Ddl but no lead compounds were found
[56], which is consistent with our results.
Our overall assessment is that BpDdl represents a
challenging target for drug discovery. However, our
progress in enabling ligand-binding studies of the
enzyme means that in future a structure-based rational
approach [57] combining crystallography with compu-
tational docking and modelling calculations would be
feasible. In similar fashion, further HTP screens can
be prosecuted but the composition of the library
would have to be carefully considered.
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